Fiscal Year:
2001
Title:
Cryopreservation of a Living Human Skin Equivalent
Agency:
HHS
Contract:
N/A
Award Amount:
$101,350.00
Abstract:
DESCRIPTION (provided by applicant): Production of a living human skin
equivalent (LSE) that is economical, mechanically durable and provides
effective barrier function for the treatment of epithelial trauma (e.g., burns
and diabetic lesions) is a highly prized goal of current efforts in tissue
engineering. Stratatech, L.L.C., is currently commercializing various products
based on the proprietary human keratinocyte cell line, NIKStm, which has been
shown to differentiate into a fully stratified living skin equivalent with
normal expression of histological markers. The limited shelf life and high
storage costs for currently available skin equivalent products limit their
therapeutic potential. We hypothesize that a non-toxic cryoprotectant system
based on saccharides specifically designed to form a glass on cooling (i.e.,
vitrify) rather than freeze will be more effective in the preservation of skin
tissue architecture and viability than current methods (i.e., treatment with
glycerol). Development of highly effective cryopreservation methods for the
NIKStm cell line represents an opportunity to provide the medical community
with a much needed supply of off-the-shelf skin graft material with long shelf
life at relatively high storage temperatures.
PROPOSED COMMERCIAL APPLICATION:
As the field of tissue engineering advances, the need for effective, non-toxic preservation methods for future products grows. Stratatech is developing living human skin equivalent products based on our proprietary NIKS (TM) cell line. The goal of this proposal is to develop technology based on recent advances in cryopreservation coupled with methods to introduce protectants into target cells. We hypothesize that by enhancing glass formation a non-toxic, high storage temperature preservation system can be achieved for living human skin equivalents, a model system with high therapeutic value. It is our belief that this technology will be applicable to a wide range of other tissues and organs.
Principal Investigator:
Paul B. Conrad
Small Business Information at Submission:
STRATATECH CORPORATION
UNIVERSITY RESEARCH PARK 505 S ROSA RD MADISON, WI 53719
EIN/Tax ID:
392025292
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned:
No
Minority-Owned:
No
HUBZone-Owned:
No